Khandelwal Laboratories Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Khandelwal Laboratories Private Limited Pharmaceutical Export Portfolio Dataset — 8 Products, $1.6M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Khandelwal Laboratories Private Limited — Pharmaceutical Exporter Profile (2026) | 8 Products, $1.6M Trade | TransData Nexus

Khandelwal Laboratories Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $1.6M Total Trade · DGFT Verified

Khandelwal Laboratories Private Limited is an Indian pharmaceutical exporter with a total trade value of $1.6M across 8 products in 3 therapeutic categories. Based on 241 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Tamoxifen ($742.7K), Methotrexate ($248.1K), Letrozole ($176.8K).

Khandelwal Laboratories Private Limited — Export Portfolio & Destination Treemap

Khandelwal Laboratories Private Limited pharmaceutical export portfolio — 8 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Khandelwal Laboratories Private Limited? — Company Overview & Market Position

Khandelwal Laboratories Private Limited (KLab) is a privately held pharmaceutical company established in 1945, headquartered in Mumbai, Maharashtra, India. The company specializes in the research and development, manufacturing, distribution, marketing, and licensing of patented pharmaceutical formulations, novel drug delivery systems (NDDS), niche active pharmaceutical ingredients (APIs), and chiral intermediates. KLab has a significant presence in the Indian market, particularly in oncology, antibiotics, pain, and spasm management sectors.

As of the latest available data, KLab's authorized and paid-up capital stands at ₹50 million (approximately $625,000 USD). The company employs over 1,000 individuals across its operations. Its registered office is located at 79/87 D. Lad Path, Kala Chowkie, Mumbai, Maharashtra, 400033, India.

What Does Khandelwal Laboratories Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Tamoxifen$742.7K 2Methotrexate

Product Portfolio — Top 8 by Export Value

Khandelwal Laboratories Private Limited exports 8 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Tamoxifen	Advanced Oncology	$742.7K	32	5.0%	5
2	Methotrexate	Immunosuppressants	$248.1K	109	0.7%	13
3	Letrozole	Advanced Oncology	$176.8K	27	0.6%	10
4	Bleomycin	Advanced Oncology	$158.4K	17	2.8%	8
5	Gefitinib	Advanced Oncology	$139.8K	11	2.1%	5
6	Etoposide	Oncology	$98.1K	14	0.9%	10
7	Epirubicin	Advanced Oncology	$32.6K	12	0.5%	12
8	Vincristine	Oncology	$27.3K	19	1.3%	14

Khandelwal Laboratories Private Limited exports 8 pharmaceutical products across 3 therapeutic categories with a total export value of $1.6M. The top category is Advanced Oncology (77.0% of portfolio), followed by Immunosuppressants (15.3%), indicating a concentrated portfolio with the top 5 products accounting for 90.3% of total export value.

Khandelwal Laboratories Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

KLab operates three WHO-GMP approved manufacturing facilities in India:

Thane Facility: Specializes in oncology products, focusing on both formulations and APIs.

Rudrapur Facility: Dedicated to tablet manufacturing.

Dadra Facility: Handles injectable formulations.

These facilities enable KLab to produce a diverse range of pharmaceutical products, catering to various therapeutic areas.

3Key Leadership

The leadership team at KLab includes:

Mr. Sanjeev Khandelwal: Managing Director

Mr. S. K. Pai Kakode: Director

Mr. G. Pinto: Vice President of Finance

Mrs. P. Omray: Technical Director

Mr. Lotlikar: Vice President of Quality

Mr. S. Sharma: International Licensing

This team oversees KLab's strategic direction and operational execution.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Khandelwal Laboratories Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

KLab's products are subject to regulatory approvals in various international markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has pursued regulatory filings and approvals to access these markets, though specific details on approvals are not publicly disclosed. KLab's focus on oncology and other therapeutic areas positions it to meet the stringent requirements of these regions.

2Emerging Markets

KLab has expanded its presence in emerging markets such as Africa, Latin America, and Southeast Asia. The company has identified and out-licensed products to these regions, leveraging its expertise in oncology and other therapeutic areas. While specific details on WHO prequalification are not available, KLab's strategic initiatives suggest efforts to enhance access to these markets.

3Geographic Strategy

KLab's geographic strategy involves a diversified approach, focusing on both domestic and international markets. The company's significant export value of $1.6 million USD across 241 shipments indicates a strong international presence. However, the portfolio concentration, with the top five products accounting for 90.3% of exports, suggests a reliance on a limited product range. This concentration may pose risks if market dynamics shift.

Khandelwal Laboratories Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding KLab's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's focus on oncology and other therapeutic areas suggests potential engagement with the FDA, but without explicit information, a comprehensive assessment cannot be made.

2WHO & EU GMP

KLab's manufacturing facilities are WHO-GMP approved, indicating compliance with international standards for Good Manufacturing Practices. However, specific details regarding EU GMP certificates and EDQM status are not publicly disclosed. The company's focus on oncology and other therapeutic areas suggests potential alignment with EU standards, but without explicit information, a comprehensive assessment cannot be made.

3CDSCO & Indian Regulatory

KLab holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has approvals from state drug controllers. The company has also obtained export No Objection Certificates (NOCs), facilitating its international trade activities. These regulatory approvals underscore KLab's compliance with Indian pharmaceutical regulations.

Khandelwal Laboratories Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

KLab operates in a competitive landscape, particularly in the oncology and generic pharmaceutical sectors. While specific competitors are not identified in the available data, the company's focus on oncology products positions it against both domestic and international players. The market share distribution of KLab's top five products indicates a competitive presence, though the high portfolio concentration may impact its competitive positioning.

2Key Differentiators

KLab's key differentiators include its extensive experience since 1945, a strong focus on oncology products, and a significant number of patents granted or pending. The company's WHO-GMP approved manufacturing facilities and its ability to provide contract manufacturing for over 10 companies further enhance its competitive edge.

3Strategic Position

KLab's current strategic direction emphasizes the development and marketing of generic pharmaceutical formulations, with a strong focus on oncology products. The recent acquisition of its non-oncology business by Aurobindo Pharma Limited's subsidiary, Auro Pharma Limited, on January 1, 2026, indicates a strategic shift. This move allows KLab to concentrate more on its oncology portfolio, potentially strengthening its position in this therapeutic area.

Buyer Due Diligence Brief — Evaluating Khandelwal Laboratories Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

KLab has a track record of consistent export volume, with a total export value of $1.6 million USD across 241 shipments. The company's portfolio concentration, with the top five products accounting for 90.3% of exports, suggests a focused approach. While this concentration may pose risks, KLab's established presence in oncology and other therapeutic areas indicates reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering KLab as a supplier:

WHO-GMP Certification: To ensure compliance with international manufacturing standards.

EU GMP Certification: To confirm adherence to European manufacturing standards.

FDA Facility Registration: To ascertain eligibility for exporting to the United States.

Frequently Asked Questions — Khandelwal Laboratories Private Limited

How many pharmaceutical products does Khandelwal Laboratories Private Limited export from India?

Khandelwal Laboratories Private Limited exports 8 pharmaceutical products across 3 therapeutic categories. The top exports are Tamoxifen ($742.7K), Methotrexate ($248.1K), Letrozole ($176.8K), Bleomycin ($158.4K), Gefitinib ($139.8K). Total export value is $1.6M.

What is Khandelwal Laboratories Private Limited's total pharmaceutical export value?

Khandelwal Laboratories Private Limited's total pharmaceutical export value is $1.6M, based on 241 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Khandelwal Laboratories Private Limited cover?

Khandelwal Laboratories Private Limited exports across 3 therapeutic categories. The largest are Advanced Oncology (77.0%, 5 products), Immunosuppressants (15.3%, 1 products), Oncology (7.7%, 2 products).

Get Full Khandelwal Laboratories Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.